(INSM) Insmed - Ratings and Ratios
Therapies, Treatments, Medications, Inhalation, Gene Therapy
INSM EPS (Earnings per Share)
INSM Revenue
Description: INSM Insmed
Insmed Incorporated is a biotechnology company that develops and commercializes therapies for serious and rare diseases globally, with a focus on the US, Europe, and Japan. The companys lead product, ARIKAYCE, is used to treat refractory nontuberculous mycobacterial lung infections.
The companys pipeline includes several promising candidates: brensocatib, a DPP1 inhibitor in Phase 3 trials for bronchiectasis; treprostinil palmitil inhalation powder, a treprostinil prodrug in Phase 3 trials for pulmonary hypertension associated with interstitial lung disease; and a gene therapy for Duchenne muscular dystrophy in Phase 1 trials. These candidates have the potential to drive future growth and expand the companys presence in the rare disease market.
From a financial perspective, Insmeds market capitalization is approximately $18.6 billion, indicating a significant presence in the biotechnology sector. The companys return on equity (ROE) is negative, which is not uncommon for biotech companies with significant R&D expenses. Key performance indicators (KPIs) to watch include revenue growth from ARIKAYCE sales, progress in clinical trials for pipeline candidates, and cash burn rate. A closer look at the companys cash position, research and development expenses, and sales and marketing expenses will provide further insights into its financial health.
To evaluate Insmeds potential, its essential to monitor the progress of its pipeline candidates, particularly brensocatib and treprostinil palmitil, as they advance through clinical trials. Additionally, the companys ability to maintain a strong cash position and manage its expenses will be crucial in driving future growth. Key metrics to track include the companys cash runway, R&D expense as a percentage of revenue, and the sales growth rate of ARIKAYCE.
INSM Stock Overview
| Market Cap in USD | 30,127m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2000-06-01 |
INSM Stock Ratings
| Growth Rating | 74.6% |
| Fundamental | 33.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 66.5% |
| Analyst Rating | 4.74 of 5 |
INSM Dividends
Currently no dividends paidINSM Growth Ratios
| Growth Correlation 3m | 91.7% |
| Growth Correlation 12m | 55.7% |
| Growth Correlation 5y | 39.5% |
| CAGR 5y | 82.72% |
| CAGR/Max DD 3y | 2.54 |
| CAGR/Mean DD 3y | 7.94 |
| Sharpe Ratio 12m | 0.95 |
| Alpha | 0.01 |
| Beta | 0.647 |
| Volatility | 41.96% |
| Current Volume | 1448.5k |
| Average Volume 20d | 2025.1k |
| Stop Loss | 139.5 (-3.6%) |
| Signal | 1.47 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-1.03b TTM) > 0 and > 6% of Revenue (6% = 23.9m TTM) |
| FCFTA -0.28 (>2.0%) and ΔFCFTA 1.90pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 444.6% (prev 272.1%; Δ 172.5pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.34 (>3.0%) and CFO -844.6m > Net Income -1.03b (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 6.68 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (189.3m) change vs 12m ago 22.37% (target <= -2.0% for YES) |
| Gross Margin 75.40% (prev 76.84%; Δ -1.44pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 18.56% (prev 18.15%; Δ 0.41pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -11.18 (EBITDA TTM -934.8m / Interest Expense TTM 84.7m) >= 6 (WARN >= 3) |
Altman Z'' -8.99
| (A) 0.71 = (Total Current Assets 2.08b - Total Current Liabilities 311.7m) / Total Assets 2.48b |
| (B) -1.99 = Retained Earnings (Balance) -4.94b / Total Assets 2.48b |
| warn (B) unusual magnitude: -1.99 — check mapping/units |
| (C) -0.44 = EBIT TTM -947.1m / Avg Total Assets 2.14b |
| (D) -4.01 = Book Value of Equity -4.93b / Total Liabilities 1.23b |
| Total Rating: -8.99 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 33.50
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -2.45% = -1.22 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.44 = 2.41 |
| 5. Debt/Ebitda -0.58 = -2.50 |
| 6. ROIC - WACC (= -73.41)% = -12.50 |
| 7. RoE -195.4% = -2.50 |
| 8. Rev. Trend 92.68% = 6.95 |
| 9. EPS Trend -42.74% = -2.14 |
What is the price of INSM shares?
Over the past week, the price has changed by -1.66%, over one month by +13.73%, over three months by +42.48% and over the past year by +97.66%.
Is Insmed a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of INSM is around 178.15 USD . This means that INSM is currently undervalued and has a potential upside of +23.07% (Margin of Safety).
Is INSM a buy, sell or hold?
- Strong Buy: 14
- Buy: 5
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the INSM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 155.1 | 7.1% |
| Analysts Target Price | 155.1 | 7.1% |
| ValueRay Target Price | 198.1 | 36.9% |
Last update: 2025-09-05 04:47
INSM Fundamental Data Overview
CCE Cash And Equivalents = 1.86b USD (Cash And Short Term Investments, last quarter)
P/S = 75.6767
P/B = 24.271
Beta = 0.967
Revenue TTM = 398.1m USD
EBIT TTM = -947.1m USD
EBITDA TTM = -934.8m USD
Long Term Debt = 538.5m USD (from longTermDebt, last quarter)
Short Term Debt = 6.66m USD (from shortTermDebt, last quarter)
Debt = 545.2m USD (Calculated: Short Term 6.66m + Long Term 538.5m)
Net Debt = -708.8m USD (from netDebt column, last quarter)
Enterprise Value = 28.82b USD (30.13b + Debt 545.2m - CCE 1.86b)
Interest Coverage Ratio = -11.18 (Ebit TTM -947.1m / Interest Expense TTM 84.7m)
FCF Yield = -2.45% (FCF TTM -705.8m / Enterprise Value 28.82b)
FCF Margin = -177.3% (FCF TTM -705.8m / Revenue TTM 398.1m)
Net Margin = -259.8% (Net Income TTM -1.03b / Revenue TTM 398.1m)
Gross Margin = 75.40% ((Revenue TTM 398.1m - Cost of Revenue TTM 97.9m) / Revenue TTM)
Tobins Q-Ratio = -5.84 (set to none) (Enterprise Value 28.82b / Book Value Of Equity -4.93b)
Interest Expense / Debt = 3.90% (Interest Expense 21.2m / Debt 545.2m)
Taxrate = 21.0% (US default)
NOPAT = -947.1m (EBIT -947.1m, no tax applied on loss)
Current Ratio = 6.68 (Total Current Assets 2.08b / Total Current Liabilities 311.7m)
Debt / Equity = 0.44 (Debt 545.2m / last Quarter total Stockholder Equity 1.25b)
Debt / EBITDA = -0.58 (Net Debt -708.8m / EBITDA -934.8m)
Debt / FCF = -0.77 (Debt 545.2m / FCF TTM -705.8m)
Total Stockholder Equity = 529.4m (last 4 quarters mean)
RoA = -41.71% (Net Income -1.03b, Total Assets 2.48b )
RoE = -195.4% (Net Income TTM -1.03b / Total Stockholder Equity 529.4m)
RoCE = -88.69% (Ebit -947.1m / (Equity 529.4m + L.T.Debt 538.5m))
RoIC = -65.10% (NOPAT -947.1m / Invested Capital 1.45b)
WACC = 8.31% (E(30.13b)/V(30.67b) * Re(8.40%)) + (D(545.2m)/V(30.67b) * Rd(3.90%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 4.17%
Discount Rate = 8.40% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -705.8m)
EPS Correlation: -42.74 | EPS CAGR: -29.93% | SUE: -1.31 | # QB: 0
Revenue Correlation: 92.68 | Revenue CAGR: 18.26% | SUE: N/A | # QB: None
Additional Sources for INSM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle